Neumora Therapeutics, Inc.

Biotechnology • Healthcare • Watertown, MA, United States • NMRA (NMS)

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

857 760 0900 490 Arsenal Way, Watertown, MA 02472, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance

Yahoo Finance • Oct 30

Momentum Shift: Will Neumora Therapeutics Inc. stock benefit from AI adoption - New Guidance & Consistent Income Trade Recommendations - moha.gov.vn

moha.gov.vn • Dec 27

Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative

Quiver Quantitative • Oct 30

Neumora Therapeutics stock jumps after positive obesity drug data - Investing.com

Investing.com • Oct 27

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

MarketBeat • Dec 18

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Neumora Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Neumora Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Neumora Therapeutics, Inc. have?

Neumora Therapeutics, Inc. has approximately 95 employees.

What industry is Neumora Therapeutics, Inc. in?

Neumora Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Neumora Therapeutics, Inc. a publicly traded company?

Yes, Neumora Therapeutics, Inc. is publicly traded under the ticker symbol NMRA on the NMS. The company has a market capitalization of approximately $0.30 billion.

Where is Neumora Therapeutics, Inc. headquartered?

Neumora Therapeutics, Inc. is headquartered in Watertown, MA, United States at 490 Arsenal Way, Watertown, MA 02472, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.